
Vor Biopharma (VOR) Stock Forecast & Price Target
Vor Biopharma (VOR) Analyst Ratings
Bulls say
Vor Biopharma has strategically enhanced its asset, financial, and management frameworks to position itself for potential commercialization within 24-30 months. The company is expected to benefit from favorable efficacy and safety profiles of its therapies, which may drive adoption rates relative to competitors, particularly in treatment for various hematological malignancies. Moreover, promising clinical trial outcomes indicate significant improvements in key health measures, suggesting strong potential for expansion opportunities and increased market penetration.
Bears say
Vor Biopharma Inc's stock outlook has been negatively impacted by a significant decrease in its price target, which has been revised down from $55 to $32 per diluted share due to share dilution associated with a recent capital raise. The disappointing offer price of $10.00 represents a substantial ~47% discount to the previous closing price of $18.80, indicating a lack of confidence in the stock's current valuation. Furthermore, challenges related to the ongoing clinical landscape, including unattractive enrollment conditions for complement inhibitors and potential risks associated with therapy, contribute to the overall pessimism surrounding the company's financial future.
This aggregate rating is based on analysts' research of Vor Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Vor Biopharma (VOR) Analyst Forecast & Price Prediction
Start investing in Vor Biopharma (VOR)
Order type
Buy in
Order amount
Est. shares
0 shares